| Form N-CSR Cover | 6 Months Ended |
| Aug. 31, 2024 | |
| Shareholder Report [Line Items] | |
| Document Type | N-CSRS |
| Amendment Flag | false |
| Registrant Name | Tema ETF Trust |
| Entity Central Index Key | 0001944285 |
| Entity Investment Company Type | N-1A |
| Document Period End Date | Aug. 31, 2024 |
| Shareholder Report | 6 Months Ended | |
| Aug. 31, 2024 USD ($) $ / shares | ||
| Shareholder Report [Line Items] | ||
| Document Type | N-CSRS | |
| Amendment Flag | false | |
| Registrant Name | Tema ETF Trust | |
| Entity Central Index Key | 0001944285 | |
| Entity Investment Company Type | N-1A | |
| Document Period End Date | Aug. 31, 2024 | |
| Tema American Reshoring ETF | ||
| Shareholder Report [Line Items] | ||
| Fund Name | Tema American Reshoring ETF | |
| Class Name | Tema American Reshoring ETF | |
| Trading Symbol | RSHO | |
| Security Exchange Name | NYSEArca | |
| Annual or Semi-Annual Statement [Text Block] | This semi-annual shareholder report contains important information about the Tema American Reshoring ETF for the period of March 1, 2024, to August 31, 2024. | |
| Shareholder Report Annual or Semi-Annual | semi-annual shareholder report | |
| Additional Information [Text Block] | You can find additional information about the Fund at https://temaetfs.com/funds . You can also request this information by contacting us toll-free at 1-888-744-1377 . | |
| Additional Information Phone Number | 1-888-744-1377 | |
| Additional Information Website | https://temaetfs.com/funds | |
| Expenses [Text Block] | WHAT WERE THE FUND COSTS FOR THE LAST SIX MONTHS? (based on a hypothetical $10,000 investment) Fund Name Costs of a $10,000 investment Costs paid as a percentage of a $10,000 investment * Tema American Reshoring ETF $39 0.75% | [1] |
| Expenses Paid, Amount | $ 39 | |
| Expense Ratio, Percent | 0.75% | |
| Updated Performance Information Location [Text Block] | Visit https://temaetfs.com/funds for more recent performance information. | |
| Net Assets | $ 101,507,085 | |
| Holdings Count | $ / shares | 31 | |
| Investment Company Portfolio Turnover | 4% | |
| Additional Fund Statistics [Text Block] | KEY FUND STATISTICS (as of August 31, 2024) Net Assets $101,507,085 Number of Holdings 31 Portfolio Turnover 4% | |
| Holdings [Text Block] | Top 10 Issuers (% of net assets) Applied Industrial Technologies, Inc. 5.3% Eaton Corp. PLC 4.9% Clean Harbors, Inc. 4.9% SPX Technologies, Inc. 4.6% Linde PLC 4.4% CRH PLC 4.4% Ingersoll Rand, Inc. 4.3% Primoris Services Corp. 4.1% Fluor Corp. 3.7% Federal Signal Corp. 3.6% Top Sectors * (% of net assets) Industrials 70.7% Materials 18.5% Health Care 6.3% Consumer Discretionary 2.5% Information Technology 1.3% Cash & Other 0.7% | [2] |
| Updated Prospectus Web Address | https://temaetfs.com/funds. | |
| Tema GLP-1, Obesity & Cardiometabolic ETF | ||
| Shareholder Report [Line Items] | ||
| Fund Name | Tema GLP-1, Obesity & Cardiometabolic ETF | |
| Class Name | Tema GLP-1, Obesity & Cardiometabolic ETF | |
| Trading Symbol | HRTS | |
| Security Exchange Name | NASDAQ | |
| Annual or Semi-Annual Statement [Text Block] | This semi-annual shareholder report contains important information about the Tema GLP-1, Obesity & Cardiometabolic ETF for the period of March 1, 2024, to August 31, 2024. | |
| Shareholder Report Annual or Semi-Annual | semi-annual shareholder report | |
| Additional Information [Text Block] | You can find additional information about the Fund at https://temaetfs.com/ funds . You can also request this information by contacting us toll-free at 1-888-744-1377 . | |
| Additional Information Phone Number | 1-888-744-1377 | |
| Additional Information Website | https://temaetfs.com/funds | |
| Expenses [Text Block] | WHAT WERE THE FUND COSTS FOR THE LAST SIX MONTHS? (based on a hypothetical $10,000 investment) Fund Name Costs of a $10,000 investment Costs paid as a percentage of a $10,000 investment * Tema GLP-1, Obesity & Cardiometabolic ETF $39 0.75% | [3] |
| Expenses Paid, Amount | $ 39 | |
| Expense Ratio, Percent | 0.75% | |
| Updated Performance Information Location [Text Block] | Visit https://temaetfs.com/funds for more recent performance information. | |
| Net Assets | $ 87,841,811 | |
| Holdings Count | $ / shares | 45 | |
| Investment Company Portfolio Turnover | 29% | |
| Additional Fund Statistics [Text Block] | KEY FUND STATISTICS (as of August 31, 2024) Net Assets $87,841,811 Number of Holdings 45 Portfolio Turnover 29% | |
| Holdings [Text Block] | Top 10 Issuers (% of net assets) Amgen, Inc. 7.1% Eli Lilly & Co. 5.5% Alnylam Pharmaceuticals, Inc. 5.3% Vertex Pharmaceuticals, Inc. 4.4% Novo Nordisk AS 4.4% Bridgebio Pharma, Inc. 4.1% Chugai Pharmaceutical Co. Ltd. 3.7% Ultragenyx Pharmaceutical, Inc. 3.5% Cytokinetics, Inc. 3.3% AstraZeneca PLC 3.1% Top Sectors * (% of net assets) Health Care 97.8% Financials 0.9% Cash & Other 1.3% | [4] |
| Updated Prospectus Web Address | https://temaetfs.com/funds. | |
| Tema Luxury ETF | ||
| Shareholder Report [Line Items] | ||
| Fund Name | Tema Luxury ETF | |
| Class Name | Tema Luxury ETF | |
| Trading Symbol | LUX | |
| Security Exchange Name | NYSEArca | |
| Annual or Semi-Annual Statement [Text Block] | This semi-annual shareholder report contains important information about the Tema Luxury ETF for the period of March 1, 2024, to August 31, 2024. | |
| Shareholder Report Annual or Semi-Annual | semi-annual shareholder report | |
| Additional Information [Text Block] | You can find additional information about the Fund at https://temaetfs.com/funds . You can also request this information by contacting us toll-free at 1-888-744-1377 . | |
| Additional Information Phone Number | 1-888-744-1377 | |
| Additional Information Website | https://temaetfs.com/funds | |
| Expenses [Text Block] | WHAT WERE THE FUND COSTS FOR THE LAST SIX MONTHS? (based on a hypothetical $10,000 investment) Fund Name Costs of a $10,000 investment Costs paid as a percentage of a $10,000 investment * Tema Luxury ETF $36 0.75% | [5] |
| Expenses Paid, Amount | $ 36 | |
| Expense Ratio, Percent | 0.75% | |
| Updated Performance Information Location [Text Block] | Visit https://temaetfs.com/funds for more recent performance information. | |
| Net Assets | $ 2,811,112 | |
| Holdings Count | $ / shares | 29 | |
| Investment Company Portfolio Turnover | 16% | |
| Additional Fund Statistics [Text Block] | KEY FUND STATISTICS (as of August 31, 2024) Net Assets $2,811,112 Number of Holdings 29 Portfolio Turnover 16% | |
| Holdings [Text Block] | Top 10 Issuers (% of net assets) Cie Financiere Richemont SA 9.0% Hermes International SCA 8.4% First American Treasury Obligations Fund 6.6% LVMH Moet Hennessy Louis Vuitton SE 5.3% Ferrari NV 4.9% L’Oreal SA 4.8% Pernod Ricard SA 4.6% Hilton Worldwide Holdings, Inc. 4.5% Viking Holdings Ltd. (Ordinary Shares) 4.5% Marriott International, Inc. 4.2% Top Sectors * (% of net assets) Consumer Discretionary 67.6% Consumer Staples 19.1% Management of Companies and Enterprises 4.5% Health Care 1.7% Cash & Other 7.1% | [6] |
| Updated Prospectus Web Address | https://temaetfs.com/funds. | |
| Tema Monopolies and Oligopolies ETF | ||
| Shareholder Report [Line Items] | ||
| Fund Name | Tema Monopolies and Oligopolies ETF | |
| Class Name | Tema Monopolies and Oligopolies ETF | |
| Trading Symbol | TOLL | |
| Security Exchange Name | CboeBZX | |
| Annual or Semi-Annual Statement [Text Block] | This semi-annual shareholder report contains important information about the Tema Monopolies and Oligopolies ETF for the period of March 1, 2024, to August 31, 2024. | |
| Shareholder Report Annual or Semi-Annual | semi-annual shareholder report | |
| Additional Information [Text Block] | You can find additional information about the Fund at https://temaetfs.com/funds . You can also request this information by contacting us toll-free at 1-888-744-1377 . | |
| Additional Information Phone Number | 1-888-744-1377 | |
| Additional Information Website | https://temaetfs.com/funds | |
| Expenses [Text Block] | WHAT WERE THE FUND COSTS FOR THE LAST SIX MONTHS? (based on a hypothetical $10,000 investment) Fund Name Costs of a $10,000 investment Costs paid as a percentage of a $10,000 investment * Tema Monopolies and Oligopolies ETF $36 0.68% | [7] |
| Expenses Paid, Amount | $ 36 | |
| Expense Ratio, Percent | 0.68% | |
| Updated Performance Information Location [Text Block] | Visit https://temaetfs.com/funds for more recent performance information. | |
| Net Assets | $ 11,659,645 | |
| Holdings Count | $ / shares | 33 | |
| Investment Company Portfolio Turnover | 22% | |
| Additional Fund Statistics [Text Block] | KEY FUND STATISTICS (as of August 31, 2024) Net Assets $11,659,645 Number of Holdings 33 Portfolio Turnover 22% | |
| Holdings [Text Block] | Top 10 Issuers (% of net assets) Moody’s Corp. 5.9% General Electric Co. 5.8% Intercontinental Exchange, Inc. 5.6% Visa, Inc. 4.7% S&P Global, Inc. 4.6% Fair Isaac Corp. 4.2% Sherwin-Williams Co. 4.0% Teradyne, Inc. 3.5% Tyler Technologies, Inc. 3.4% Equifax, Inc. 3.4% Top Sectors * (% of net assets) Financials 28.9% Industrials 25.4% Information Technology 24.7% Health Care 12.3% Materials 6.8% Cash & Other 1.9% | [8] |
| Updated Prospectus Web Address | https://temaetfs.com/funds. | |
| Tema Neuroscience and Mental Health ETF | ||
| Shareholder Report [Line Items] | ||
| Fund Name | Tema Neuroscience and Mental Health ETF | |
| Class Name | Tema Neuroscience and Mental Health ETF | |
| Trading Symbol | MNTL | |
| Security Exchange Name | NASDAQ | |
| Annual or Semi-Annual Statement [Text Block] | This semi-annual shareholder report contains important information about the Tema Neuroscience and Mental Health ETF for the period of March 1, 2024, to August 31, 2024. | |
| Shareholder Report Annual or Semi-Annual | semi-annual shareholder report | |
| Additional Information [Text Block] | You can find additional information about the Fund at https://temaetfs.com/ funds . You can also request this information by contacting us toll-free at 1-888-744-1377 . | |
| Additional Information Phone Number | 1-888-744-1377 | |
| Additional Information Website | https://temaetfs.com/funds | |
| Expenses [Text Block] | WHAT WERE THE FUND COSTS FOR THE LAST SIX MONTHS? (based on a hypothetical $10,000 investment) Fund Name Costs of a $10,000 investment Costs paid as a percentage of a $10,000 investment * Tema Neuroscience and Mental Health ETF $39 0.75% | [9] |
| Expenses Paid, Amount | $ 39 | |
| Expense Ratio, Percent | 0.75% | |
| Updated Performance Information Location [Text Block] | Visit https://temaetfs.com/funds for more recent performance information. | |
| Net Assets | $ 12,031,399 | |
| Holdings Count | $ / shares | 47 | |
| Investment Company Portfolio Turnover | 14% | |
| Additional Fund Statistics [Text Block] | KEY FUND STATISTICS (as of August 31, 2024) Net Assets $12,031,399 Number of Holdings 47 Portfolio Turnover 14% | |
| Holdings [Text Block] | Top 10 Issuers (% of net assets) Vertex Pharmaceuticals, Inc. 6.7% Regeneron Pharmaceuticals, Inc. 5.7% Eli Lilly & Co. 5.6% Denali Therapeutics, Inc. 4.4% Argenx SE 4.3% Alnylam Pharmaceuticals, Inc. 4.1% Neurocrine Biosciences, Inc. 4.1% Teva Pharmaceutical Industries Ltd. 4.0% Biogen, Inc. 3.8% UCB SA 3.5% Top Sectors * (% of net assets) Health Care 99.1% Cash & Other 0.9% | [10] |
| Updated Prospectus Web Address | https://temaetfs.com/funds. | |
| Tema Oncology ETF | ||
| Shareholder Report [Line Items] | ||
| Fund Name | Tema Oncology ETF | |
| Class Name | Tema Oncology ETF | |
| Trading Symbol | CANC | |
| Security Exchange Name | NASDAQ | |
| Annual or Semi-Annual Statement [Text Block] | This semi-annual shareholder report contains important information about the Tema Oncology ETF for the period of March 1, 2024, to August 31, 2024. | |
| Shareholder Report Annual or Semi-Annual | semi-annual shareholder report | |
| Additional Information [Text Block] | You can find additional information about the Fund at https://temaetfs.com/funds . You can also request this information by contacting us toll-free at 1-888-744-1377 . | |
| Additional Information Phone Number | 1-888-744-1377 | |
| Additional Information Website | https://temaetfs.com/funds | |
| Expenses [Text Block] | WHAT WERE THE FUND COSTS FOR THE LAST SIX MONTHS? (based on a hypothetical $10,000 investment) Fund Name Costs of a $10,000 investment Costs paid as a percentage of a $10,000 investment * Tema Oncology ETF $39 0.75% | [11] |
| Expenses Paid, Amount | $ 39 | |
| Expense Ratio, Percent | 0.75% | |
| Updated Performance Information Location [Text Block] | Visit https://temaetfs.com/funds for more recent performance information. | |
| Net Assets | $ 51,280,837 | |
| Holdings Count | $ / shares | 48 | |
| Investment Company Portfolio Turnover | 26% | |
| Additional Fund Statistics [Text Block] | KEY FUND STATISTICS (as of August 31, 2024) Net Assets $51,280,837 Number of Holdings 48 Portfolio Turnover 26% | |
| Holdings [Text Block] | Top 10 Issuers (% of net assets) Regeneron Pharmaceuticals, Inc. 6.1% AstraZeneca PLC 5.9% Amgen, Inc. 4.3% Merck & Co., Inc. 4.3% Daiichi Sankyo Co. Ltd. 3.8% Argenx SE 3.7% Chugai Pharmaceutical Co. Ltd. 3.6% Blueprint Medicines Corp. 3.3% Illumina, Inc. 3.3% Revolution Medicines, Inc. 3.1% Top Sectors * (% of net assets) Health Care 99.2% Cash & Other 0.8% | [12] |
| Updated Prospectus Web Address | https://temaetfs.com/funds. | |
| [1] * Annualized. * The Global Industry Classification Standard (“GICS®”) was developed by and/or is the exclusive property of MSCI, Inc. (“MSCI”) and Standard & Poor’s Financial Services LLC (“S&P”). GICS® is a service mark of MSCI and S&P and has been licensed for use by U.S. Bank Global Fund Services. * Annualized. * The Global Industry Classification Standard (“GICS®”) was developed by and/or is the exclusive property of MSCI, Inc. (“MSCI”) and Standard & Poor’s Financial Services LLC (“S&P”). GICS® is a service mark of MSCI and S&P and has been licensed for use by U.S. Bank Global Fund Services. * Annualized. * The Global Industry Classification Standard (“GICS®”) was developed by and/or is the exclusive property of MSCI, Inc. (“MSCI”) and Standard & Poor’s Financial Services LLC (“S&P”). GICS® is a service mark of MSCI and S&P and has been licensed for use by U.S. Bank Global Fund Services. * Annualized. * The Global Industry Classification Standard (“GICS®”) was developed by and/or is the exclusive property of MSCI, Inc. (“MSCI”) and Standard & Poor’s Financial Services LLC (“S&P”). GICS® is a service mark of MSCI and S&P and has been licensed for use by U.S. Bank Global Fund Services. * Annualized. * The Global Industry Classification Standard (“GICS®”) was developed by and/or is the exclusive property of MSCI, Inc. (“MSCI”) and Standard & Poor’s Financial Services LLC (“S&P”). GICS® is a service mark of MSCI and S&P and has been licensed for use by U.S. Bank Global Fund Services. * Annualized. * The Global Industry Classification Standard (“GICS®”) was developed by and/or is the exclusive property of MSCI, Inc. (“MSCI”) and Standard & Poor’s Financial Services LLC (“S&P”). GICS® is a service mark of MSCI and S&P and has been licensed for use by U.S. Bank Global Fund Services. | ||
| Label | Element | Value |
| Tema American Reshoring ETF | Applied Industrial Technologies, Inc. [Member] | ||
| Holdings [Line Items] | oef_HoldingsLineItems | |
| Percent of Net Asset Value | oef_PctOfNav | 5.30% |
| Tema American Reshoring ETF | Eaton Corp. PLC [Member] | ||
| Holdings [Line Items] | oef_HoldingsLineItems | |
| Percent of Net Asset Value | oef_PctOfNav | 4.90% |
| Tema American Reshoring ETF | Clean Harbors, Inc. [Member] | ||
| Holdings [Line Items] | oef_HoldingsLineItems | |
| Percent of Net Asset Value | oef_PctOfNav | 4.90% |
| Tema American Reshoring ETF | SPX Technologies, Inc. [Member] | ||
| Holdings [Line Items] | oef_HoldingsLineItems | |
| Percent of Net Asset Value | oef_PctOfNav | 4.60% |
| Tema American Reshoring ETF | Linde PLC [Member] | ||
| Holdings [Line Items] | oef_HoldingsLineItems | |
| Percent of Net Asset Value | oef_PctOfNav | 4.40% |
| Tema American Reshoring ETF | CRH PLC [Member] | ||
| Holdings [Line Items] | oef_HoldingsLineItems | |
| Percent of Net Asset Value | oef_PctOfNav | 4.40% |
| Tema American Reshoring ETF | Ingersoll Rand, Inc. [Member] | ||
| Holdings [Line Items] | oef_HoldingsLineItems | |
| Percent of Net Asset Value | oef_PctOfNav | 4.30% |
| Tema American Reshoring ETF | Primoris Services Corp. [Member] | ||
| Holdings [Line Items] | oef_HoldingsLineItems | |
| Percent of Net Asset Value | oef_PctOfNav | 4.10% |
| Tema American Reshoring ETF | Fluor Corp. [Member] | ||
| Holdings [Line Items] | oef_HoldingsLineItems | |
| Percent of Net Asset Value | oef_PctOfNav | 3.70% |
| Tema American Reshoring ETF | Federal Signal Corp. [Member] | ||
| Holdings [Line Items] | oef_HoldingsLineItems | |
| Percent of Net Asset Value | oef_PctOfNav | 3.60% |
| Tema American Reshoring ETF | Industrials [Member] | ||
| Holdings [Line Items] | oef_HoldingsLineItems | |
| Percent of Net Asset Value | oef_PctOfNav | 70.70% |
| Tema American Reshoring ETF | Materials [Member] | ||
| Holdings [Line Items] | oef_HoldingsLineItems | |
| Percent of Net Asset Value | oef_PctOfNav | 18.50% |
| Tema American Reshoring ETF | Health Care [Member] | ||
| Holdings [Line Items] | oef_HoldingsLineItems | |
| Percent of Net Asset Value | oef_PctOfNav | 6.30% |
| Tema American Reshoring ETF | Consumer Discretionary [Member] | ||
| Holdings [Line Items] | oef_HoldingsLineItems | |
| Percent of Net Asset Value | oef_PctOfNav | 2.50% |
| Tema American Reshoring ETF | Information Technology [Member] | ||
| Holdings [Line Items] | oef_HoldingsLineItems | |
| Percent of Net Asset Value | oef_PctOfNav | 1.30% |
| Tema American Reshoring ETF | Cash & Other [Member] | ||
| Holdings [Line Items] | oef_HoldingsLineItems | |
| Percent of Net Asset Value | oef_PctOfNav | 0.70% |
| Label | Element | Value |
| Tema GLP-1, Obesity & Cardiometabolic ETF | Amgen, Inc. [Member] | ||
| Holdings [Line Items] | oef_HoldingsLineItems | |
| Percent of Net Asset Value | oef_PctOfNav | 7.10% |
| Tema GLP-1, Obesity & Cardiometabolic ETF | Eli Lilly & Co. [Member] | ||
| Holdings [Line Items] | oef_HoldingsLineItems | |
| Percent of Net Asset Value | oef_PctOfNav | 5.50% |
| Tema GLP-1, Obesity & Cardiometabolic ETF | Alnylam Pharmaceuticals, Inc. [Member] | ||
| Holdings [Line Items] | oef_HoldingsLineItems | |
| Percent of Net Asset Value | oef_PctOfNav | 5.30% |
| Tema GLP-1, Obesity & Cardiometabolic ETF | Vertex Pharmaceuticals, Inc. [Member] | ||
| Holdings [Line Items] | oef_HoldingsLineItems | |
| Percent of Net Asset Value | oef_PctOfNav | 4.40% |
| Tema GLP-1, Obesity & Cardiometabolic ETF | Novo Nordisk AS [Member] | ||
| Holdings [Line Items] | oef_HoldingsLineItems | |
| Percent of Net Asset Value | oef_PctOfNav | 4.40% |
| Tema GLP-1, Obesity & Cardiometabolic ETF | Bridgebio Pharma, Inc. [Member] | ||
| Holdings [Line Items] | oef_HoldingsLineItems | |
| Percent of Net Asset Value | oef_PctOfNav | 4.10% |
| Tema GLP-1, Obesity & Cardiometabolic ETF | Chugai Pharmaceutical Co. Ltd. [Member] | ||
| Holdings [Line Items] | oef_HoldingsLineItems | |
| Percent of Net Asset Value | oef_PctOfNav | 3.70% |
| Tema GLP-1, Obesity & Cardiometabolic ETF | Ultragenyx Pharmaceutical, Inc. [Member] | ||
| Holdings [Line Items] | oef_HoldingsLineItems | |
| Percent of Net Asset Value | oef_PctOfNav | 3.50% |
| Tema GLP-1, Obesity & Cardiometabolic ETF | Cytokinetics, Inc. [Member] | ||
| Holdings [Line Items] | oef_HoldingsLineItems | |
| Percent of Net Asset Value | oef_PctOfNav | 3.30% |
| Tema GLP-1, Obesity & Cardiometabolic ETF | AstraZeneca PLC [Member] | ||
| Holdings [Line Items] | oef_HoldingsLineItems | |
| Percent of Net Asset Value | oef_PctOfNav | 3.10% |
| Tema GLP-1, Obesity & Cardiometabolic ETF | Health Care [Member] | ||
| Holdings [Line Items] | oef_HoldingsLineItems | |
| Percent of Net Asset Value | oef_PctOfNav | 97.80% |
| Tema GLP-1, Obesity & Cardiometabolic ETF | Financials [Member] | ||
| Holdings [Line Items] | oef_HoldingsLineItems | |
| Percent of Net Asset Value | oef_PctOfNav | 0.90% |
| Tema GLP-1, Obesity & Cardiometabolic ETF | Cash & Other [Member] | ||
| Holdings [Line Items] | oef_HoldingsLineItems | |
| Percent of Net Asset Value | oef_PctOfNav | 1.30% |
| Label | Element | Value |
| Tema Luxury ETF | Cie Financiere Richemont SA [Member] | ||
| Holdings [Line Items] | oef_HoldingsLineItems | |
| Percent of Net Asset Value | oef_PctOfNav | 9% |
| Tema Luxury ETF | Hermes International SCA [Member] | ||
| Holdings [Line Items] | oef_HoldingsLineItems | |
| Percent of Net Asset Value | oef_PctOfNav | 8.40% |
| Tema Luxury ETF | First American Treasury Obligations Fund [Member] | ||
| Holdings [Line Items] | oef_HoldingsLineItems | |
| Percent of Net Asset Value | oef_PctOfNav | 6.60% |
| Tema Luxury ETF | LVMH Moet Hennessy Louis Vuitton SE [Member] | ||
| Holdings [Line Items] | oef_HoldingsLineItems | |
| Percent of Net Asset Value | oef_PctOfNav | 5.30% |
| Tema Luxury ETF | Ferrari NV [Member] | ||
| Holdings [Line Items] | oef_HoldingsLineItems | |
| Percent of Net Asset Value | oef_PctOfNav | 4.90% |
| Tema Luxury ETF | L'Oreal SA [Member] | ||
| Holdings [Line Items] | oef_HoldingsLineItems | |
| Percent of Net Asset Value | oef_PctOfNav | 4.80% |
| Tema Luxury ETF | Pernod Ricard SA [Member] | ||
| Holdings [Line Items] | oef_HoldingsLineItems | |
| Percent of Net Asset Value | oef_PctOfNav | 4.60% |
| Tema Luxury ETF | Hilton Worldwide Holdings, Inc. [Member] | ||
| Holdings [Line Items] | oef_HoldingsLineItems | |
| Percent of Net Asset Value | oef_PctOfNav | 4.50% |
| Tema Luxury ETF | Viking Holdings Ltd. (Ordinary Shares) [Member] | ||
| Holdings [Line Items] | oef_HoldingsLineItems | |
| Percent of Net Asset Value | oef_PctOfNav | 4.50% |
| Tema Luxury ETF | Marriott International, Inc. [Member] | ||
| Holdings [Line Items] | oef_HoldingsLineItems | |
| Percent of Net Asset Value | oef_PctOfNav | 4.20% |
| Tema Luxury ETF | Consumer Discretionary [Member] | ||
| Holdings [Line Items] | oef_HoldingsLineItems | |
| Percent of Net Asset Value | oef_PctOfNav | 67.60% |
| Tema Luxury ETF | Consumer Staples [Member] | ||
| Holdings [Line Items] | oef_HoldingsLineItems | |
| Percent of Net Asset Value | oef_PctOfNav | 19.10% |
| Tema Luxury ETF | Management of Companies and Enterprises [Member] | ||
| Holdings [Line Items] | oef_HoldingsLineItems | |
| Percent of Net Asset Value | oef_PctOfNav | 4.50% |
| Tema Luxury ETF | Health Care [Member] | ||
| Holdings [Line Items] | oef_HoldingsLineItems | |
| Percent of Net Asset Value | oef_PctOfNav | 1.70% |
| Tema Luxury ETF | Cash & Other [Member] | ||
| Holdings [Line Items] | oef_HoldingsLineItems | |
| Percent of Net Asset Value | oef_PctOfNav | 7.10% |
| Label | Element | Value |
| Tema Monopolies and Oligopolies ETF | Moody's Corp. [Member] | ||
| Holdings [Line Items] | oef_HoldingsLineItems | |
| Percent of Net Asset Value | oef_PctOfNav | 5.90% |
| Tema Monopolies and Oligopolies ETF | General Electric Co. [Member] | ||
| Holdings [Line Items] | oef_HoldingsLineItems | |
| Percent of Net Asset Value | oef_PctOfNav | 5.80% |
| Tema Monopolies and Oligopolies ETF | Intercontinental Exchange, Inc. [Member] | ||
| Holdings [Line Items] | oef_HoldingsLineItems | |
| Percent of Net Asset Value | oef_PctOfNav | 5.60% |
| Tema Monopolies and Oligopolies ETF | Visa, Inc. [Member] | ||
| Holdings [Line Items] | oef_HoldingsLineItems | |
| Percent of Net Asset Value | oef_PctOfNav | 4.70% |
| Tema Monopolies and Oligopolies ETF | S&P Global, Inc. [Member] | ||
| Holdings [Line Items] | oef_HoldingsLineItems | |
| Percent of Net Asset Value | oef_PctOfNav | 4.60% |
| Tema Monopolies and Oligopolies ETF | Fair Isaac Corp. [Member] | ||
| Holdings [Line Items] | oef_HoldingsLineItems | |
| Percent of Net Asset Value | oef_PctOfNav | 4.20% |
| Tema Monopolies and Oligopolies ETF | Sherwin-Williams Co. [Member] | ||
| Holdings [Line Items] | oef_HoldingsLineItems | |
| Percent of Net Asset Value | oef_PctOfNav | 4% |
| Tema Monopolies and Oligopolies ETF | Teradyne, Inc. [Member] | ||
| Holdings [Line Items] | oef_HoldingsLineItems | |
| Percent of Net Asset Value | oef_PctOfNav | 3.50% |
| Tema Monopolies and Oligopolies ETF | Tyler Technologies, Inc. [Member] | ||
| Holdings [Line Items] | oef_HoldingsLineItems | |
| Percent of Net Asset Value | oef_PctOfNav | 3.40% |
| Tema Monopolies and Oligopolies ETF | Equifax, Inc. [Member] | ||
| Holdings [Line Items] | oef_HoldingsLineItems | |
| Percent of Net Asset Value | oef_PctOfNav | 3.40% |
| Tema Monopolies and Oligopolies ETF | Financials [Member] | ||
| Holdings [Line Items] | oef_HoldingsLineItems | |
| Percent of Net Asset Value | oef_PctOfNav | 28.90% |
| Tema Monopolies and Oligopolies ETF | Industrials [Member] | ||
| Holdings [Line Items] | oef_HoldingsLineItems | |
| Percent of Net Asset Value | oef_PctOfNav | 25.40% |
| Tema Monopolies and Oligopolies ETF | Information Technology [Member] | ||
| Holdings [Line Items] | oef_HoldingsLineItems | |
| Percent of Net Asset Value | oef_PctOfNav | 24.70% |
| Tema Monopolies and Oligopolies ETF | Health Care [Member] | ||
| Holdings [Line Items] | oef_HoldingsLineItems | |
| Percent of Net Asset Value | oef_PctOfNav | 12.30% |
| Tema Monopolies and Oligopolies ETF | Materials [Member] | ||
| Holdings [Line Items] | oef_HoldingsLineItems | |
| Percent of Net Asset Value | oef_PctOfNav | 6.80% |
| Tema Monopolies and Oligopolies ETF | Cash & Other [Member] | ||
| Holdings [Line Items] | oef_HoldingsLineItems | |
| Percent of Net Asset Value | oef_PctOfNav | 1.90% |
| Label | Element | Value |
| Tema Neuroscience and Mental Health ETF | Vertex Pharmaceuticals, Inc. [Member] | ||
| Holdings [Line Items] | oef_HoldingsLineItems | |
| Percent of Net Asset Value | oef_PctOfNav | 6.70% |
| Tema Neuroscience and Mental Health ETF | Regeneron Pharmaceuticals, Inc. [Member] | ||
| Holdings [Line Items] | oef_HoldingsLineItems | |
| Percent of Net Asset Value | oef_PctOfNav | 5.70% |
| Tema Neuroscience and Mental Health ETF | Eli Lilly & Co. [Member] | ||
| Holdings [Line Items] | oef_HoldingsLineItems | |
| Percent of Net Asset Value | oef_PctOfNav | 5.60% |
| Tema Neuroscience and Mental Health ETF | Denali Therapeutics, Inc. [Member] | ||
| Holdings [Line Items] | oef_HoldingsLineItems | |
| Percent of Net Asset Value | oef_PctOfNav | 4.40% |
| Tema Neuroscience and Mental Health ETF | Argenx SE [Member] | ||
| Holdings [Line Items] | oef_HoldingsLineItems | |
| Percent of Net Asset Value | oef_PctOfNav | 4.30% |
| Tema Neuroscience and Mental Health ETF | Alnylam Pharmaceuticals, Inc. [Member] | ||
| Holdings [Line Items] | oef_HoldingsLineItems | |
| Percent of Net Asset Value | oef_PctOfNav | 4.10% |
| Tema Neuroscience and Mental Health ETF | Neurocrine Biosciences, Inc. [Member] | ||
| Holdings [Line Items] | oef_HoldingsLineItems | |
| Percent of Net Asset Value | oef_PctOfNav | 4.10% |
| Tema Neuroscience and Mental Health ETF | Teva Pharmaceutical Industries Ltd. [Member] | ||
| Holdings [Line Items] | oef_HoldingsLineItems | |
| Percent of Net Asset Value | oef_PctOfNav | 4% |
| Tema Neuroscience and Mental Health ETF | Biogen, Inc. [Member] | ||
| Holdings [Line Items] | oef_HoldingsLineItems | |
| Percent of Net Asset Value | oef_PctOfNav | 3.80% |
| Tema Neuroscience and Mental Health ETF | UCB SA [Member] | ||
| Holdings [Line Items] | oef_HoldingsLineItems | |
| Percent of Net Asset Value | oef_PctOfNav | 3.50% |
| Tema Neuroscience and Mental Health ETF | Health Care [Member] | ||
| Holdings [Line Items] | oef_HoldingsLineItems | |
| Percent of Net Asset Value | oef_PctOfNav | 99.10% |
| Tema Neuroscience and Mental Health ETF | Cash & Other [Member] | ||
| Holdings [Line Items] | oef_HoldingsLineItems | |
| Percent of Net Asset Value | oef_PctOfNav | 0.90% |
| Label | Element | Value |
| Tema Oncology ETF | Regeneron Pharmaceuticals, Inc. [Member] | ||
| Holdings [Line Items] | oef_HoldingsLineItems | |
| Percent of Net Asset Value | oef_PctOfNav | 6.10% |
| Tema Oncology ETF | AstraZeneca PLC [Member] | ||
| Holdings [Line Items] | oef_HoldingsLineItems | |
| Percent of Net Asset Value | oef_PctOfNav | 5.90% |
| Tema Oncology ETF | Amgen, Inc. [Member] | ||
| Holdings [Line Items] | oef_HoldingsLineItems | |
| Percent of Net Asset Value | oef_PctOfNav | 4.30% |
| Tema Oncology ETF | Merck & Co., Inc. [Member] | ||
| Holdings [Line Items] | oef_HoldingsLineItems | |
| Percent of Net Asset Value | oef_PctOfNav | 4.30% |
| Tema Oncology ETF | Daiichi Sankyo Co. Ltd. [Member] | ||
| Holdings [Line Items] | oef_HoldingsLineItems | |
| Percent of Net Asset Value | oef_PctOfNav | 3.80% |
| Tema Oncology ETF | Argenx SE [Member] | ||
| Holdings [Line Items] | oef_HoldingsLineItems | |
| Percent of Net Asset Value | oef_PctOfNav | 3.70% |
| Tema Oncology ETF | Chugai Pharmaceutical Co. Ltd. [Member] | ||
| Holdings [Line Items] | oef_HoldingsLineItems | |
| Percent of Net Asset Value | oef_PctOfNav | 3.60% |
| Tema Oncology ETF | Blueprint Medicines Corp. [Member] | ||
| Holdings [Line Items] | oef_HoldingsLineItems | |
| Percent of Net Asset Value | oef_PctOfNav | 3.30% |
| Tema Oncology ETF | Illumina, Inc. [Member] | ||
| Holdings [Line Items] | oef_HoldingsLineItems | |
| Percent of Net Asset Value | oef_PctOfNav | 3.30% |
| Tema Oncology ETF | Revolution Medicines, Inc. [Member] | ||
| Holdings [Line Items] | oef_HoldingsLineItems | |
| Percent of Net Asset Value | oef_PctOfNav | 3.10% |
| Tema Oncology ETF | Health Care [Member] | ||
| Holdings [Line Items] | oef_HoldingsLineItems | |
| Percent of Net Asset Value | oef_PctOfNav | 99.20% |
| Tema Oncology ETF | Cash & Other [Member] | ||
| Holdings [Line Items] | oef_HoldingsLineItems | |
| Percent of Net Asset Value | oef_PctOfNav | 0.80% |
